Objective
to report the 5-year clinical outcomes of FFR-guided PCI versus CABG for the treatment of patients with 3-vessel disease
Study
multicentre randomised trial
Population
patients with 3-vessel disease and without left main disease
Endpoints
5-year incidence of composite of death, stroke or MI
Conclusion
Among patients with 3-vessel disease, there was no significant difference between FFR-guided PCI and CABG in terms of 5-year incidence of death, stroke or MI.
Fearon et al. Lancet. 2025 Mar 28:S0140-6736(25)00505-7.